These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2481847)

  • 1. External pancreatic secretion in the rat: supramaximal inhibition induced by the cholecystokinin octapeptide [CCK(26-33)] and analogs altered on the 28-29 bond.
    Nagain C; Mendre C; Rodriguez M; Bernard C; Martinez J; Rozé C
    Peptides; 1989; 10(5):1041-7. PubMed ID: 2481847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large and prolonged in vivo response of pancreatic secretion to phenylethylamide and phenylethylester derivatives of Boc-[Nle28-Nle31]CCK(26-33) in the rat.
    Nagain C; Lignon MF; Galas MC; Rodriguez M; Martinez J; Rozé C
    Peptides; 1992; 13(6):1127-32. PubMed ID: 1494494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between phospholipid breakdown, intracellular calcium mobilization and enzyme secretion in rat pancreatic acini treated with Boc-[Nle28, Nle31]-CCK-7 and JMV180, two cholecystokinin analogues.
    Lignon MF; Galas MC; Rodriguez M; Martinez J
    Cell Signal; 1990; 2(4):339-46. PubMed ID: 1701321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of guanine nucleotide regulatory protein in stimulation of exocrine pancreatic secretion by cholecystokinin in isolated rat pancreatic acini].
    Matozaki T
    Nihon Naibunpi Gakkai Zasshi; 1988 Oct; 64(10):1051-64. PubMed ID: 2463183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists.
    Nagain C; Galas MC; Lignon MF; Rodriguez M; Martinez J; Rozé C
    Pancreas; 1991 May; 6(3):275-81. PubMed ID: 1713671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activities of peptide and pseudo-peptide analogs of the C-terminal octapeptide of cholecystokinin on pancreatic secretion in the rat.
    Nagain C; Rodriguez M; Martinez J; Rozé C
    Peptides; 1987; 8(6):1023-8. PubMed ID: 3441441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of phorbol ester on cholecystokinin octapeptide-evoked exocrine pancreatic secretion in the rat.
    Francis LP; Camello PJ; Singh J; Salido GM; Madrid JA
    J Physiol; 1990 Dec; 431():27-37. PubMed ID: 1712842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amylase secretion by isolated pancreatic acini after chronic cholecystokinin treatment in vivo.
    Otsuki M; Williams JA
    Am J Physiol; 1983 Jun; 244(6):G683-8. PubMed ID: 6190411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amylase secretion by isolated pancreatic acini after acute cholecystokinin treatment in vivo.
    Otsuki M; Okabayashi Y; Ohki A; Hootman SR; Baba S; Williams JA
    Am J Physiol; 1984 Apr; 246(4 Pt 1):G419-25. PubMed ID: 6326589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supramaximal CCK and CCh concentrations abolish VIP potentiation by inhibiting adenylyl cyclase activity.
    Akiyama T; Hirohata Y; Okabayashi Y; Imoto I; Otsuki M
    Am J Physiol; 1998 Nov; 275(5):G1202-8. PubMed ID: 9815052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar potencies of CCK-8 and its analogue BOC(Nle28;Nle31)CCK27-33 on the self-stimulation behaviour both are antagonized by a newly synthesized cyclic CCK analogue.
    Heidbreder C; Roques BP; De Witte P
    Neuropeptides; 1989; 13(2):89-94. PubMed ID: 2739884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
    Stark HA; Sharp CM; Sutliff VE; Martinez J; Jensen RT; Gardner JD
    Biochim Biophys Acta; 1989 Feb; 1010(2):145-50. PubMed ID: 2463851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
    Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
    J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Ca2+ oscillations induced by cholecystokinin (CCK) and its analog OPE in rat pancreatic acinar cells by low-level protein kinase C activation without transition of the CCK receptor from a high- to low-affinity state.
    Gaisano HY; Miller LJ; Foskett JK
    Pflugers Arch; 1994 Jul; 427(5-6):455-62. PubMed ID: 7971144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CCK analogues and bombesin: a detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species.
    Bianchi BR; Miller TR; Witte DG; Lin CW
    J Pharmacol Exp Ther; 1994 Feb; 268(2):996-1002. PubMed ID: 7509394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G protein in stimulation of PI hydrolysis by CCK in isolated rat pancreatic acinar cells.
    Matozaki T; Sakamoto C; Nagao M; Nishizaki H; Baba S
    Am J Physiol; 1988 Nov; 255(5 Pt 1):E652-9. PubMed ID: 2461094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cholecystokinin octapeptide on the pancreatic exocrine secretion in the pig.
    Cuber JC; Corring T; Levenez F; Bernard C; Chayvialle JA
    Can J Physiol Pharmacol; 1989 Nov; 67(11):1391-7. PubMed ID: 2627679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supramaximal inhibition of cholecystokinin-induced pancreatic amylase release involves desensitization to cytoplasmic Ca2+.
    Nilsson J; Sjödin L; Gylfe E
    Scand J Gastroenterol; 1994 Jun; 29(6):561-8. PubMed ID: 7521537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue.
    Marseigne I; Roy P; Dor A; Durieux C; Pélaprat D; Reibaud M; Blanchard JC; Roques BP
    J Med Chem; 1989 Feb; 32(2):445-9. PubMed ID: 2464062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.